Steatotic liver disease (SLD) displays a dynamic and complex disease phenotype.
Consequently, the metabolic dysfunction-associated steatotic liver disease …

Over the past decade, there have been several guideline updates for the diagnosis and
management of non-alcoholic fatty liver disease (NAFLD), which is the most common …

The 21st century is characterized by an increasing incidence and prevalence of obesity and
the burden of its associated comorbidities, especially cardiometabolic diseases, which are …

Background The role of metabolic/inflammatory hormonal systems in metabolic dysfunction
associated steatotic liver disease (MASLD) remains to be fully elucidated. Purpose To report …

Metabolic disorders such as obesity, type 2 diabetes mellitus (T2DM), dyslipidemia, and non-
alcoholic fatty liver disease (NAFLD)–henceforth named metabolic dysfunction-associated …

Diabetes mellitus is a risk factor for muscle loss and sarcopenia. Sodium-glucose co-
transporter 2 inhibitors (SGLT2i) or “gliflozins” are one of the newest anti-hyperglycemic …

To the Editor: 15 Non-alcoholic fatty liver disease (NAFLD) is the most prevalent chronic liver
disorder 16 globally, affecting approximately one-fourth of the world's population [1] …

Objective While studies have documented how metabolic dysfunction-associated steatotic
liver disease (MASLD) can contribute to cardiovascular disease (CVD), whether MASLD is …

Background Growth differentiation factor 15 (GDF15) is a mitokine, the role of which, total or
H-specific, in modulating energy metabolism and homeostasis in obesity-related diseases …

Abstract Introduction and Objectives In a recent development, a cohort of hepatologists has
proposed altering the nomenclature of non-alcoholic fatty liver disease (NAFLD) to …